Arcus Biosciences (RCUS) grants director RSUs and stock options

Rhea-AI Filing Summary

Arcus Biosciences director Patrick Machado received new equity awards. On June 11, 2026 he was granted 5,700 shares of common stock in the form of restricted stock units, which vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders, and become fully vested if the Company undergoes a change in control.

He was also granted stock options for 16,900 shares at an exercise price of $23.30 per share, expiring on June 10, 2036, with the same vesting and change‑in‑control acceleration terms. Following these awards, Machado directly holds 44,300 shares of Arcus Biosciences common stock. These are compensation-related grants rather than open‑market purchases.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Machado Patrick

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	16,900	$0.00	--
Grant/Award	Common Stock	5,700	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 16,900 shares (Direct, null); Common Stock — 44,300 shares (Direct, null)

Footnotes (1)

1. Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.

Key Figures

RSU grant: 5,700 shares Option grant size: 16,900 shares Option exercise price: $23.30 per share +2 more

5 metrics

RSU grant 5,700 shares Restricted stock units granted on June 11, 2026

Option grant size 16,900 shares Stock options granted on June 11, 2026

Option exercise price $23.30 per share Stock option exercise price

Option expiration June 10, 2036 Stock option expiration date

Shares held after grant 44,300 shares Common stock directly held following grants

Key Terms

restricted stock units, change in control, stock option, annual meeting of stockholders

4 terms

restricted stock units financial

"Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

change in control financial

"The RSUs will become fully vested in the event the Company is subject to a change in control"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

stock option financial

"The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

annual meeting of stockholders financial

"vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Machado Patrick

(Last) (First) (Middle)

C/O ARCUS BIOSCIENCES, INC.

3928 POINT EDEN WAY

(Street)

HAYWARD CALIFORNIA 94545

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arcus Biosciences, Inc. [ RCUS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/11/2026		A		5,700(1)	A	$0	44,300	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$23.3	06/11/2026		A		16,900		(2)	06/10/2036	Stock Option (Rights to Buy)	16,900	$0	16,900	D

Explanation of Responses:

1. Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.

2. The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.

Remarks:

	/s/ Carolyn Tang, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Arcus Biosciences (RCUS) disclose for Patrick Machado?

Arcus Biosciences reported that director Patrick Machado received equity compensation. He was granted 5,700 restricted stock units and stock options for 16,900 shares on June 11, 2026, both vesting by June 11, 2027 or at the next annual stockholder meeting.

How many restricted stock units did Patrick Machado receive from Arcus Biosciences (RCUS)?

Patrick Machado received 5,700 restricted stock units from Arcus Biosciences. These RSUs vest in full on the earlier of June 11, 2027 or the next annual stockholder meeting and fully vest if the company experiences a change in control event.

What are the details of the stock options granted to Patrick Machado by Arcus Biosciences (RCUS)?

Machado was granted stock options for 16,900 shares at an exercise price of $23.30 per share. The options vest fully on the earlier of June 11, 2027 or the next annual meeting and become fully exercisable if Arcus Biosciences undergoes a change in control.

How many Arcus Biosciences (RCUS) shares does Patrick Machado hold after these grants?

After the June 11, 2026 grants, Patrick Machado directly holds 44,300 shares of Arcus Biosciences common stock. This figure reflects his non-derivative holdings following receipt of the 5,700 restricted stock units reported in the same Form 4 filing.

When do Patrick Machado’s new Arcus Biosciences (RCUS) equity awards vest?

Both the 5,700 restricted stock units and the 16,900-share stock option grant vest in full on the earlier of June 11, 2027 or the next annual stockholder meeting. They also fully vest or become exercisable if the company is subject to a change in control.